VIDEO: ‘Practice changing’ data on early-stage triple-negative breast cancer immunotherapy

ByCory Perla

In this video, Sara Hurvitz, MD, discussed the "practice changing" data from the KEYNOTE-522 phase 3 trial reviewed at 39th Miami Breast Cancer Conference.

"The data from KEYNOTE really have been practice changing but it does raise a number of questions," said Hurvitz, an associate professor at David Geffen School of Medicine at UCLA and medical director of Jonsson Comprehensive Cancer Center Clinical Research Unit.

She said those questions include how to select the best candidates for pembrolizumab treatment and whether it needs to be given in neoadjuvant and adjuvant settings.

Published by:

Sources/Disclosures

Collapse

Disclosures: Disclosures: Hurvitz reports contracted research/preclinical work paid to institution by Ambrx, Amgen, Arvinas, Astra Zeneca, Bayer, CytomX, Daiichi-Sankyo, Dignitana, Eli Lilly, Genentech/Roche, Gilead, GlaxoSmithKline, Immunomedics, Macrogenics, Novartis, Pfizer, Phoenix Molecular Designs, OBI Pharma, Orinove, Pieris, PUMA, Radius, Samumed, Sanofi, Seagen and Zymeworks; national/international PI from Daiichi-Sankyo, Genentech/Roche, Novartis and Seagen; serving on a steering committee for Daiichi-Sankyo/AstraZeneca, Eli Lilly, Genentech/Roche, Novartis and Sanofi; travel expenses from Eli Lilly (2019); and uncompensated ad boards and/or consulting for 4DPharma, Ambrx, Amgen, Artios, Arvinas, Biotheranostics, Daiichi Sankyo, Dantari, Eli Lilly, Genentech/Roche, Immunomedics, Macrogenics, Novartis, NK Max, Pieris, Pyxis and Seagen.

Take Homes from Miami Breast Cancer Conference: Targeted Therapies

Read more

VIDEO: ‘Practice changing’ data on early-stage triple-negative breast cancer immunotherapy

Related Content